Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,350.17 -3.86 (-0.07%) Dow
38,856.50 +49.17 (+0.13%) Nasdaq
17,175.75 -12.15 (-0.07%) Bitcoin USD
71,080.99 -388.48 (-0.54%) CMC Crypto 200
1,522.39 -2.41 (-0.16%)
Ikena Oncology, Inc. (IKNA)
- Simply Wall St.
It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year
Key Insights Ikena Oncology's Annual General Meeting to take place on 7th of June CEO Mark Manfredi's total...
- GlobeNewswire
UPDATE – Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development
- GlobeNewswire
Ikena Oncology Announces Strategic Update
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development
